StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
INDPIndaptus Therapeutics, Inc.
stockpulse.co.kr
Nasdaq
$3.16▼ 0.63%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $357.8MShares out 1.100M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

18
  • 2d agoAfter-hours26.10.23 05:06
    SCHEDULE 13D/AOwnership#●●●#●●●

    Indaptus Therapeutics, Inc.

    SINO LION VENTURES Ltd has filed a SCHEDULE 13D/A to update its beneficial ownership status in Indaptus Therapeutics, Inc. This filing serves as an official disclosure regarding changes in the investor's equity position.…more

    $3.16-0.63%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 2d agoAfter-hours26.10.23 05:05
    SCHEDULE 13D/AOwnership

    Indaptus Therapeutics, Inc.

    Dai Junyi has filed a SCHEDULE 13D/A regarding their beneficial ownership in Indaptus Therapeutics, Inc. The filing provides an update on the reporting person's shareholding status and investment intent.…more

    $3.16-0.63%vs prev close
    View filingShare
  • 2d agoAfter-hours26.10.23 05:05
    SCHEDULE 13D/AOwnership

    Indaptus Therapeutics, Inc.

    Yao Yun has filed a SCHEDULE 13D/A regarding their beneficial ownership in Indaptus Therapeutics, Inc. This filing formalizes the changes in the investor's equity position.…more

    $3.16-0.63%vs prev close
    View filingShare

17 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.10Pre-market26.09.10 19:19
    Bullish#●●●#●●●

    Indaptus Therapeutics Announces $24M Private Placement

    Indaptus Therapeutics has announced a private placement of over 20 million shares to raise approximately $24 million in gross proceeds. The funds are intended for working capital and research and development, resulting in share dilution for existing investors.…more

    $3.16-0.63%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 8.13Pre-market26.08.13 20:00

    ●●●●●●●● ●●●●● ●●●●●●

    Indaptus Therapeutics has discontinued its Decoy20 clinical program and is currently evaluating strategic alternatives, including potential business combinations. While the company recently bolstered its cash position through a private placement, it currently has no active clinical development programs.…more

    $3.16-0.63%vs prev close
    Read sourceShareGlobeNewswire

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →